A recent study showed that thiazolidinedione-activated PPARγ had an ability to repress the proliferation of estrogen-dependent breast cancer cells and PPARγ might act as a therapeutic target in human breast cancer [10]. This evidence concerns the gene PPARG and breast cancer.